identify bleeding events that occur during the course of randomized clinical trials on various anti thrombotic medications. Among the existing guidelines for classifying bleeding events 5 , many clinical trials utilize one of two bleeding classifications: the Thrombolysis In Myocardial Infarction (TIMI) classification, and/or the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) classification. However, there are limited data on the relative merits of either scale at predicting clinical outcomes. Also the existence of these two systems often presents variable results in the reported incidence of bleeding events within the same clinical trial. For example, in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial, the rate of TIMI major bleeding among patients treated with the platelet inhibitor, eptifibatide was 3.0%, and that of GUSTO severe bleeding in this same group was 1.1%, and the proportion of patients to have no TIMI bleeding (84.2%) also differs from that of patients to have no GUSTO bleeding (68.8%) 6 . We analyzed data from two in-hospital randomized clinical trials to compare the association between the different degrees of in-hospital TIMI and GUSTO bleeding and short clinical outcomes. • Patients were included in the study after obtaining informed consent. The selection of patients having Acute Coronary Syndrome.
Methods
• Exclusion criterias Old MI Acute LVF
• Sampling technique:
Purposive type of non-probability sampling
• Sample size: 128
• Data collection & procedure:
Concomitant treatment with aspirin (dose ranges between 80 and 325 mg daily) and enoxaparin, a low molecular weight heparin (LMWH) were recommended by protocol in the trial. The use of other medications and procedures were at the discretion of the treating physicians.
Definition: The TIMI bleeding classification is a laboratory-based scale 7 while the GUSTO bleeding classification is a clinically based scale 8 ( Table 1 ). The TIMI definition of bleeding uses four categories: major, minor, minimal, and none. The GUSTO bleeding definition also uses four categories: severe or lifethreatening, moderate, mild, and none.
Data on the date, time, severity, and location (including "unidentifiable") of each in-hospital bleeding event was collected prospectively. Detailed clinical data, including treatments (such as blood transfusion), baseline, and nadir hemoglobin or hematocrit values after each bleeding event, and hemodynamic status during each bleeding event, was collected on all patients in both trials. For patients who will be experienced more than one bleeding episode, only the most severe bleeding episode was considered. 
Discussion:
This study showed that increasing mean age, higher mean weight, hypertension, diabetes mellitus, and hyperlipidemia were associated with increasing bleeding risk in GUSTO score. In case of TIMI score young age is associated with minor bleeding risk, but higher mean weight, diabetes mellitus and hyperlipidemia were associated with increasing bleeding risk. Sunil et al 9 in a large study (n= 15454) found similar association baseline characteristics with increasing bleeding risk in GUSTO score. However, older age in TIMI minor bleeding, and significant association of hypertension but no association of hyperlipidemia with major TIMI bleeding in their study differ with our study.
Thus, our study has shown that both the GUSTO and TIMI bleeding scales identify patients at increased risk for adverse clinical events and has important implications for both clinical care and clinical research. Our results add to other previous studies by demonstrating that that bleeding complications, regardless of severity, are associated with worse clinical outcomes among patients with acute ischemic heart disease in whom thrombolytic therapy is not used.
Finally, including both bleeding deûnitions in the same mode, GUSTO bleeding was associated with a worse prognosis and that TIMI bleeding did not affect the risk among patients who also met criteria for GUSTO bleeding. In terms of adverse outcomes, assessment of bleeding using clinical criteria is more important than using laboratory criteria 9 . 
